On June 10, 2026, the openFDA drug enforcement database logged recall number D-0555-2026: Asclemed USA Inc., based in Torrance, California, is pulling Duloxetine DR Capsules, 30 mg, in 30-count bottles, Rx only, after the discovery of a nitrosamine impurity above the level FDA considers safe. The product was relabeled by Enovachem Pharmaceuticals and marketed by Ajanta Pharma USA Inc. By the numbers, this is a small event: just 50 bottles, two lots (050725G-30 and 050725F-30), both carrying a June 30, 2026 expiration date. But the reason behind it is anything but small.
The recall was classified Class II, meaning the impurity is a situation in which use of the product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm. The recall was firm-initiated and voluntary, with the firm notifying its accounts by letter. The recall status is listed as ongoing. What turned a quiet relabeling operation into a federal enforcement record was a single line in the openFDA file describing the reason.
"CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit."— openFDA Drug Enforcement Report D-0555-2026, source
What is a nitrosamine impurity, and why does FDA treat it as a recall trigger?
Nitrosamines are a class of compounds that form when secondary or tertiary amines react with nitrosating agents, and several of them are probable human carcinogens at sustained exposure. The variant named in this recall, N-nitroso-duloxetine, is a nitrosamine drug-substance-related impurity, or NDSRI — meaning the carcinogenic fragment is derived from the active pharmaceutical ingredient itself, not from a solvent or contaminant. That distinction matters. NDSRIs are intrinsic to the drug's own chemistry, which makes them far harder to design out than a stray manufacturing residue. FDA sets an acceptable intake limit for each nitrosamine, expressed in nanograms per day, and any lot that exceeds it is considered adulterated under current good manufacturing practice, the CGMP standard the openFDA record cites directly.
The duloxetine molecule, a serotonin-norepinephrine reuptake inhibitor sold originally as Cymbalta and now overwhelmingly as a generic for depression, anxiety, and chronic pain, contains a secondary amine that can in principle nitrosate. That structural vulnerability is exactly why FDA has spent the better part of a decade building a nitrosamine testing and limit-setting regime that now reaches deep into the generic supply chain.
Why a 50-bottle recall is bigger than it looks
Read in isolation, D-0555-2026 is trivial — 50 bottles is a rounding error against the millions of duloxetine prescriptions filled in the United States every month. But read against the openFDA stream it appears in, it is a data point in the single most expensive quality story in modern generic manufacturing. The nitrosamine problem first surfaced at scale in 2018, when valsartan and the broader family of sartan blood-pressure drugs were found to contain NDMA and NDEA, forcing recalls that emptied pharmacy shelves and reshuffled global supply. It widened to ranitidine, the heartburn drug Zantac, which was withdrawn entirely, and to metformin, the world's most prescribed diabetes medication. Each wave taught the same lesson: nitrosamine risk is not a one-off contamination event but a structural feature of how certain small molecules are synthesized and stored.
For the generics business, the financial logic is unforgiving. Generic margins are thin by design — that is the entire point of the abbreviated approval pathway — and the cost of nitrosamine testing, reformulation, and recall logistics lands on producers who often sell a drug for pennies a tablet. A single NDSRI finding can force a company to re-validate an entire manufacturing line, requalify suppliers, and absorb the carrying cost of quarantined inventory. The 50 bottles named here represent the visible tip; the invisible part is the testing burden every duloxetine producer now carries to stay on the right side of an acceptable intake limit that FDA continues to refine.
The disclosure mechanics behind the record
The Asclemed action illustrates how layered the modern generic supply chain has become, and how that layering complicates accountability. The capsules were relabeled by Enovachem Pharmaceuticals in Torrance and marketed by Ajanta Pharma USA — three distinct corporate names attached to a single 30 mg capsule. When a nitrosamine finding lands, the recall is initiated by whichever entity holds the regulatory relationship for the affected lots, but the root cause typically sits upstream at the active-ingredient or finished-dose manufacturer. The openFDA record captures the who and the what; it does not resolve where in the chain the impurity originated, which is a recurring limitation of enforcement data as a business-intelligence source.
For investors and procurement teams watching the generic injectable and solid-dose space, the practical signal is this: NDSRI recalls are now a baseline operating risk for any amine-containing molecule, and they arrive without warning in the enforcement feed. The recall was initiated on May 14, 2026, and posted to the public database on June 10 — a roughly four-week lag between firm action and public visibility that is typical of the openFDA pipeline. Anyone relying on the database for real-time supply signals should account for that delay.
What the record does not say is also worth noting. There is no indication of a patient injury, no recall of upstream lots from other relabelers sharing the same active ingredient, and no expansion to additional strengths. The two affected lots both expire June 30, 2026, meaning much of the affected inventory was already near the end of its shelf life when the recall posted. That timing limits the real-world exposure but does not change the underlying point: a probable carcinogen formed inside a widely used generic, FDA caught it on testing, and the system worked as designed to pull it. The cost of that system — borne quietly across the generic industry — is the story the 50-bottle headline understates.
theradeals will continue tracking nitrosamine enforcement across the generic supply chain, where each individual recall is small but the cumulative compliance burden reshapes the economics of the cheapest drugs Americans take.